Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.
Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018
The first flotation of a ride hailing business, expected in early 2019, will give an exit to a range of corporate investors and will move this business model into public markets.
AstraZeneca, Merck & Co and Alexion all scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Tencent, Ping An and Bertelsmann-backed e-commerce platform Mogu has floated on the New York Stock Exchange in a $66.5m initial public offering.
AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.
The Bertelsmann automotive e-commerce platform has priced its shares at the lower end of its range to raise $20m instead of its targeted $150m.
Alibaba-backed Babytree priced its shares at the foot of its range and will raise $217m at a valuation of $1.5bn, down from $2.2bn earlier this year.
The travel booking platform, backed by Ctrip, Dalian Wanda and Tencent, has priced shares at the bottom of its range and raised $180m in its initial public offering.
The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.